Nuvo Pharmaceuticals™ Announces Second Quarter 2020 Results Release Date and Conference Call Details

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Nuvo Pharmaceuticals™ Announces Second Quarter 2020 Results Release Date and Conference Call Details

PR Newswire

MISSISSAUGA, ON, July 27, 2020 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI) (OTCQX: NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its second quarter 2020 financial results before markets open on Monday, August 10, 2020.

The Company will subsequently hold a conference call the same day, Monday, August 10, 2020 at 8:30 a.m. ET, hosted by Jesse Ledger, Nuvo's President & Chief Executive Officer and other senior management.  A question-and-answer session will follow the corporate update.

CONFERENCE CALL DETAILS

DATE:  Monday, August 10, 2020

TIME:    8:30 a.m. ET

DIAL-IN NUMBER:         416 764 8688 or 1 888 390 0546

TAPED REPLAY:          416 764 8677 or 1 888 390 0541 / REPLAY PASSCODE: 492164#

The audio webcast can be accessed at:

https://produceredition.webcasts.com/starthere.jsp?ei=1339580&tp_key=355d8230e7

An archived replay of the webcast will be available by clicking the link above.

About Nuvo Pharmaceuticals Inc.
Nuvo (TSX: NRI; OTCQX: NRIFF) is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products.  The Company targets several therapeutic areas, including pain, allergy and dermatology.  The Company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.  Nuvo's head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the U.S. Food and Drug Administration (FDA), Health Canada and E.U. approved manufacturing facility is located in Varennes, Québec, Canada.  The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S, Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the FDA.  For additional information, please visit www.nuvopharmaceuticals.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nuvo-pharmaceuticals-announces-second-quarter-2020-results-release-date-and-conference-call-details-301099835.html

SOURCE Nuvo Pharmaceuticals Inc.

Copyright CNW Group 2020

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).